To further strengthen regional supply resilience and diversify manufacturing capacity, MPP has launched a targeted regional Expression of Interest (EOI), open exclusively to eligible manufacturers from the Latin American and Caribbean region, to recruit one additional licensee for baloxavir marboxil, an innovative antiviral treatment for influenza recommended by the World Health Organization (WHO).

In May 2026, MPP and Roche signed a voluntary licence agreement to expand access to baloxavir marboxil that will enable generic manufacturers to develop, produce, and supply baloxavir in 129 low- and middle-income countries (LIMCs).  The agreement aims to expand access to baloxavir marboxil in LMICs, supporting both seasonal influenza treatment and broader pandemic preparedness and response efforts. Following a global EoI, MPP announced in September the sublicensees selected for manufacturing and supply of the product.

Building on this global licensing initiative, MPP is now seeking one additional licensee based in Latin America and the Caribbean to further strengthen regional manufacturing capacity and supply resilience. The Pan American Health Organization (PAHO) is supporting broader regional engagement around this initiative.

To support interested manufacturers in preparing their applications, MPP and PAHO will jointly host an information webinar on 1 December 2026, from 15:00 to 16:00 CET. The session will cover the licensing opportunity, application requirements and EOI portal, followed by a Q&A. Further details and registration information are provided below.

The EOI is open until 15 December 2026, at 23:59 (Central European Time).  

How to apply

Eligible manufacturers interested in applying should follow these steps:

  1. Register as an Applicant: Visit MPP’s EOI Portal and select “Register as Applicant” to provide the required information.
  2. Account approval: The MPP EOI administrator will review the submitted information and approve the registration to grant access to the portal.
  3. Complete the EOI form: Only fully completed applications submitted by the deadline will be considered.

Further details on the EOI process are available at the following link

Information Webinar – Regional Baloxavir Marboxil EOI

The Medicines Patent Pool (MPP), in collaboration with the Pan American Health Organization (PAHO), invites manufacturers from Latin America and the Caribbean to an information webinar to learn more about the regional Expression of Interest (EOI) for baloxavir marboxil. Participants will receive an overview of the licensing opportunity, practical guidance on preparing and submitting an application, and a walkthrough of MPP’s EOI portal. The session will conclude with an opportunity to ask questions.

Date: Tuesday, 1 December 2026

Time: 15:00–16:00 CET

Participation is limited to manufacturers based in Latin America and the Caribbean. 

Register for the webinar here

More about Baloxavir marboxil licence